Setting occupational exposure limits for pharmaceuticals

Occupational Medicine - State of the Art Reviews

Volumn 12, Issue 1, 1997, Pages 67-80

  Naumann, Bruce D ^a   Sargent, Edward V ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BIOAVAILABILITY; CLINICAL TRIAL; DANGEROUS GOODS; DOCUMENTATION; DRUG INDUSTRY; DRUG SURVEILLANCE PROGRAM; ENVIRONMENTAL MONITORING; HUMAN; INTERPERSONAL COMMUNICATION; LEGAL ASPECT; MAXIMUM ALLOWABLE CONCENTRATION; METHODOLOGY; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; REVIEW; RISK ASSESSMENT; SPECIES DIFFERENCE; STANDARD; TOXICITY TESTING; UNITED STATES;

ANIMALS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS; COMMUNICATION; DOCUMENTATION; DRUG INDUSTRY; ENVIRONMENTAL MONITORING; HAZARDOUS SUBSTANCES; HUMANS; MAXIMUM ALLOWABLE CONCENTRATION; NO-OBSERVED-ADVERSE-EFFECT LEVEL; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; RISK ASSESSMENT; SPECIES SPECIFICITY; TOXICITY TESTS; UNITED STATES;

EID: 33748952504     PISSN: 0885114X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. ABPI: Guidance on setting in-house occupational exposure limits for airborne therapeutic substances and their intermediates. London, The Association of British Pharmaceutical Industry, 1995.
2. ACGIH: Documentation of the threshold limit values and biological exposure indices. 6th ed. Cincinnati, American Conference of Governmental Industrial Hygienists, 1991.
3. ACGIH: Threshold Limit Values for chemical substances and physical agents and biological exposure indices. Cincinnati, American Conference of Governmental Industrial Hygienists, 1995.
4. AIHA: The AIHA 1996 Emergency Response Planning Guidelines and Workplace Environmental Exposure Level Guides Handbook. Fairfax, VA, American Industrial Hygiene Association, 1996.
5. Agius R: Occupational exposure limits for therapeutic substances. Ann Occup Hyg 33:555-562, 1989.
6. Alarie Y, Nielson GD: Sensory notation pulmonary irritation, and respiratory stimulation by airborne benzene and alkylbenzenses: Prediction of safe industrial exposure levels and correlation with their thermodynamic properties. Toxicol Appl Pharmacol 65:459-477, 1982.
7. Allen BC, Kavlock RJ, Kimmel CA, Faustman EM: Comparison of generic benchmark dose estimates with no observed adverse effect levels. Fundam Appl Toxicol 23:487-495, 1994.
8. Anderson ME: Tissue dosimetry in risk assessment, or what's the problem anyway? Drinking water and health, pharmacokinetics in risk assessment. Vol 8, Washington, DC, National Academy Press, 1987, pp 8-23.
9. Barnes DG, Dourson M: Reference dose (RfD): Description and use in health risk assessments. Regul Toxicol Pharmacol 8:471-486, 1988.
10. Bos RP, Leenars AO, Theuws JL, et al: Mutagenicity of urine from nurses handling cytostatic drugs, influence of smoking. Int Arch Occup Environ Health 50:359-369, 1982.
11. Burton DJ, Shmunes E: Health Hazard Evaluation Report 71-9. Cincinnati, Hazard Evaluation Service Branch National Institute for Occupational Safety and Health, U.S. Department of Health, Education and Welfare, 1973.
12. Brown RA, Schanker LS: Absorption of aerosolized drugs from the rat lung. Drug Metabol Disp 11:355-360, 1983.
13. Calabrese EJ: Uncertainty factors and interindividual variation. Regul Toxicol Pharmacol 5:190-196, 1985.
14. Conolly RB, Anderson ME: Biologically based pharmacodynamic models: Tools for lexicological research and risk assessment. Annu Rev Pharmacol Toxicol 31:503-523, 1991.
15. Courts II, Lozewicz S, Dalley MB, et al: Respiratory symptoms related to work in a factory manufacturing cimetidine tablets. BMJ 288:1418, 1984.
16. Crump KS: A new method for determining allowable daily intakes. Fundam Appl Toxicol 4:854-871, 1984.
17. Davidson IWE, Parker JC, Beliles RP: Biological basis for extrapolation across mammalian species. Regul Toxicol Pharmacol 6:211-237, 1986.
18. Dourson ML, Stara JF: Regulatory history and experimental support of uncertainty (safety) factors. Regul Toxicol Pharmacol 3:224-238, 1983.
19. Ekenvall L, Forsbeck M: Contact eczema produced by a β-adrenergic blocking agent (Alprenolol). Contact Dermatitis 4:190-194, 1978.
20. Falck K, Grohn P, Sorsa M, et al: Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1:1250-1251, 1979.
21. Frantz SW, Beatty PW, English JC, et al: The use of pharmacokinetics as an interpretive and predictive tool in chemical toxicology testing and risk assessment: A position paper on the appropriate use of pharmacokinetics in chemical toxicology. Regul Toxicol Pharmacol 19:317-337, 1994.
22. Galer DM, Leung HW, Sussman RG, Trzos RJ: Scientific and practical considerations for the development of occupational exposure limits (OELs) for chemical substances. Regul Toxicol Pharmacol 15:291-306, 1992.
23. Hardie RA, Savin JA, White DA, Pumford S: Quinine dermatitis: Investigation of a factory outbreak. Contact Dermatitis 4:121-124, 1978.
24. Harrington JM, Goldblatt P: Census based mortality study of pharmaceutical industry workers. Br J Ind Med 43:206-211, 1986.
25. Harrington JM, Rivera RO, Lowry LK: Occupational exposure to synthetic estrogens - the need to establish safety standards. Am Ind Hyg Assoc J 39:139-143, 1978.
26. Hattis D, Erdreich L, Ballew M: Human variability in susceptibility to toxic chemicals - a preliminary analysis of pharmacokinetic data from normal volunteers. Risk Anal 7:415-426, 1987.
27. Henschler D: The concept of occupational exposure limits. Sci Total Environ 101:9-16, 1991.
28. Health and Safety Executive: Occupational Exposure Limits. Guidance Note EH40. London, HMSO, 1989.
29. Jarabeck AM: Inhalation RfC methodology: Dosimetric adjustments and dose-response estimation of noncancer toxicity in the upper respiratory tract. Inhal Toxicol 6(suppl):301-325, 1994.
30. Kadry AM, Skowronski GA, Abdel-Rahmn MS: Evaluation of the use of uncertainty factors in deriving RfDs for some chlorinated compounds. J Toxicol Environ Health 44:83-95, 1995.
31. Kimmel CA: Quantitative approaches to human risk assessment for noncancer health effects. Neurotoxicology 11:189-198, 1990.
32. Kobayashi S: Occupational asthma due to inhalation of pharmacological dusts and other chemical agents. In Yamamura Y, et al (eds): Proceedings of the VIII International Congress of Allergology, Tokyo, 1973. New York, American Elsevier Publishing, 1974, pp 124-132.
33. Krasovskii GN: Extrapolation of experimental data from animals to man. Environ Health Persp 13:51-58, 1976.
34. Lehman AJ, Fitzhugh OG: 100-Fold margin of safety. Assoc Food Drug Off U S Q Bull 18:33-35, 1954.
35. Leung HW, Paustenbach DJ: Setting occupational exposure limits for irritant organic acids and bases based on their equilibrium dissociation constants. Appl Ind Hyg 3:115-118, 1988.
36. Lewis SC, Lynch JR, Nikiforov AI: A new approach to deriving community exposure guidelines from "no-observed-adverse-effect levels." Regul Toxicol Pharmacol 11:314-330, 1990.
37. Lewis SC: Reducing uncertainty with adjustment factors. Fundam Appl Toxicol 20:1-14, 1993.
38. Lewis SC, Nessel CS: Extrapolating subchronic test results to estimate chronic no-observed-adverse-effect levels: Factors of 10 are larger than necessary. Toxicologist 14:401, 1994.
39. McHattie GV, Rackham M, Teasdale EL: The derivation of occupational exposure limits in the pharmaceutical industry. J Soc Occup Med 38:105-108, 1988.
40. McNamara BP: Concepts in health evaluation of commercial and industrial chemicals. In Mehlman MA, Shapiro RE, Blumenthal H (eds): New Concepts in Safety Evaluation. Washington, DC, Hemisphere, 1976, pp 61-140.
41. Mordenti J, Chappell W: The use of interspecies scaling in toxicokinetics. In Yacobi A, Skelly JP, Batra VK (eds): Toxicokinetics and New Drug Development. New York, Pergamon Press, 1989, pp 42-96.
42. Naumann BD, Sargent EV, Starkman BS, et al: Performance-based exposure control limits for pharmaceutical active ingredients. Am Ind Hyg Assoc J 57:33-42, 1996.
43. Naumann BD, Weideman PA: Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients. Hum Ecol Risk Assess 1:590-613, 1995.
44. Newton RW, Browning MK, Iqbal J, et al: Adrenocortical suppression in workers manufacturing synthetic glucocortoids. BMJ 1:73-74, 1978.
45. Occupational Safety and Health Administration: Work practice guidelines for personnel dealing with antineoplastic drugs. Washington, DC, Office of Occupational Medicine, U.S. Department of Labor, 1985.
46. Patton JS, Platz RM: Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Deliv Rev 8:179-196, 1992.
47. Physicians' Desk Reference. Montvale, NJ, Medical Economics Data Production Company, 1995.
48. Peters-Volleberg GWM, De Waal EJ, Van Der Laan JW: Interspecies extrapolation in safety evaluation of human medicines in the Netherlands (1990-1992): Practical considerations. Regul Toxicol Pharmacol 20:248-258, 1994.
49. Renwick AG: Data-derived safety factors for the evaluation of food additives and environmental contaminants. Food Addit Contain 10:275-305, 1993.
50. Ritschel WA: Handbook of Basic Pharmacokinetics. 3rd ed. Hamilton, IL, Drug Intelligence Publications, Inc., 1986.
51. Sargent EV, Kirk GD: Establishing airborne exposure control limits in the pharmaceutical industry., Am Ind Hyg Assoc J 49:309-313, 1988.
52. Shmunes EJ, Taylor S, Petz LD, et al: Immunologic reactions in penicillin factory workers. Ann Allergy 36:313-323, 1976.
53. Sotaniemi EA, Sutinen S, Arranto AJ, et al: Liver damage in nurses handling cytostatic agents. Acta Med Scand 214:189, 1983.
54. Stejskal VDM, Olin R, Forsbeck M: Diagnosis of drug-induced occupational allergy by lymphocyte transformation test. In Hayes AW, Schnell RC, Miya TS (eds): Development in the Science and Practice of Toxicology. New York, Elsevier Science Publishers, 1983, pp 559-562.
55. Teichman RF, Fallon LF, Brandt-Rauf PW: Health effects on workers in the pharmaceutical industry: A review. J Soc Occup Med 38:55-57, 1988.
56. Thomas TL, Decoufle P: Mortality among workers employed in the pharmaceutical industry: A preliminary investigation. J Occup Med 21:619-621, 1979.
57. Vilanskaja FL, Steinberg GB: Modification of the intestine and other organs following exposure to antibiotics (streptomycin, tetracycline, penicillin). Gig Tr Prof Zabol 14:25-31, 1970.
58. Voisin EM, Ruthsatz M, Collins JM, Hoyle PC: Extrapolation of animal toxicity to humans: Interspecies comparisons in drug development. Regul Toxicol Pharmacol 12:107-116, 1990.
59. Weil CS, McCollister DD: Relationship between short- and long-term feeding studies in designing an effective toxicity test. Agr Food Chem 11(6):486-491, 1963.
60. Weil CS: Statistics vs. safety factors and scientific judgment in the evaluation of safety for man. Toxicol Appl Pharmacol 21:454-463, 1972.
61. Woutersen RA, Til HP, Feron VJ: Sub-acute versus sub-chronic oral toxicity study in rats: Comparative study of 82 compounds. J Appl Toxicol 4:277-280, 1984.
62. Zimmermann PF, Larsen RK, Barkley EW, et al: Recommendations for the safe handling of injectable antineoplastic drug products. Am J Hosp Pharmacol 38:1693-1695, 1981.